Clinical Trials Logo
  1. Home
  2. Chronic Myeloid Leukemia
  3. NCT02869256
  4. Details
NCT02869256 Clinical Trial

Regional Central Database Recording of Chronic Myeloid Leukemia

Chronic Myeloid Leukemia Clinical Trial

— LMC  

Official title:
Regional Central Database Recording of Chronic Myeloid Leukemia

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT02869256
Other study ID # IB2014-LMC
Secondary ID
Status Recruiting
Phase N/A
First received August 9, 2016
Last updated November 17, 2017
Start date January 2014
Est. completion date January 2024

Study information
Verified date November 2017
Source Institut Bergonié
Contact Gabriel etienne, MD
Email G.Etienne@bordeaux.unicancer.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

It will be a centralized database , multicentre (6 centers) , regional, chronic myelogenous leukemia cases of registration (CML) prospectively and retrospectively.

Description:

Given the complexity and evolution of recommendations and to harmonize these, it appears necessary to establish a central database for recording , monitoring patients with CML supported by the participating centers the region and evaluation of care practices in use .

Indeed , the main purpose of this database is to provide diagnostic and therapeutic management of reported cases of chronic myeloid leukemia and to study the prognostic factors . The main objective is to improve significantly the percentage of patients treated adequately load in the region, in the initial stages of the disease and during its evolution.

Recruitment information / eligibility
Status Recruiting
Enrollment 400
Est. completion date January 2024
Est. primary completion date January 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- chronic myeloid leukemia Diagnosis (CML) in chronic phase , accelerated or blast

- male or female patient aged 18 years or more

- Cases transmitted by referring hematologist , one of the 6 participating centers after patient's oral information

- Clinical record presented Concertation Meeting LMC Multidisciplinary coordinated by the Institute Bergonié

Exclusion Criteria:

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Practices evaluation
Practices evaluation

Locations
Country Name City State
France Centre Hospitalier Universitaire de Bordeaux Bordeaux
France Institut Bergonié Bordeaux
France Polyclinique Bordeaux Nord Bordeaux
France Centre Hospitalier Universitaire de Dax Dax
France Centre hospitalier Libourne Libourne
France Centre Hospitalier Universitaire de Pau Pau

Sponsors (1)
Lead Sponsor Collaborator
Institut Bergonié

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary compliance of the management of patients with chronic myeloid leukemia compared to the guidelines 10 years
Secondary overall survival 10 years
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Completed NCT02057185 - Occupational Status and Hematological Disease
Recruiting NCT03326310 - Selumetinib and Azacitidine in High Risk Chronic Blood Cancers Phase 1
Recruiting NCT04621851 - Retro-prospective Observational Study on Risk of Progression in CP-CML Patients Eligible for TKI Discontinuation
Completed NCT01207440 - Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) Phase 2
Not yet recruiting NCT06409936 - PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML Phase 2
Active, not recruiting NCT02917720 - 2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients Phase 2
Not yet recruiting NCT02883036 - Vitro Study of Tigecycline to Treat Chronic Myeloid Leukemia N/A
Withdrawn NCT01188889 - RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease. Phase 1/Phase 2
Completed NCT01795716 - Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body Phase 1
Completed NCT00988013 - Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies N/A
Approved for marketing NCT00905593 - Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Phase 3
Terminated NCT00573378 - Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia Phase 2
Completed NCT00469014 - Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia Phase 2
Terminated NCT00522990 - Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias Phase 1/Phase 2
Unknown status NCT00598624 - Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) Phase 2
Completed NCT00257647 - Use of SV40 Vectors to Treat Chronic Myeloid Leukemia (CML) N/A
Completed NCT00219739 - STI571 ProspectIve RandomIzed Trial: SPIRIT Phase 3
Completed NCT06148493 - Real-World Usage of Asciminib Among Patients With Chronic Myeloid Leukemia in Chronic Phase in the United States Using a Large Claims Database
Completed NCT00375219 - Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation Phase 2